Expertise in CAR T-Cell Therapy for Advanced Cancer
T-cells’ function in the immune system is to destroy abnormal or infected cells, such as viruses and cancer. In some patients, T-cells cannot detect or destroy cancer cells, or there are not enough T-cells. CAR T-cell therapy genetically modifies T-cells so they can better detect, target, and destroy cancer cells.
UT Southwestern’s cancer physicians and their experienced teams are dedicated to exceptional care, backed by the latest research, to provide the best possible results for our patients.
We offer the latest in CAR T-cell therapies – for example, we treat the second most number of pediatric patients in the world using Kymriah, an FDA-approved treatment for acute lymphoblastic leukemia (ALL).
We also have experience in CAR T-cell therapy that few medical centers can match. Cancer researchers at UT Southwestern took part in clinical trials for CAR T-cell therapy for a type of leukemia; we were one of only 13 centers in the U.S. and the only one in the region to do so. We were also one of a few U.S. medical centers participating in a clinical trial for the most advanced CAR T-cell therapy for multiple myeloma, known as BB2121. In addition, UT Southwestern Pediatric Group was one of 25 sites for the Novartis-sponsored ELIANA study, which was the first global clinical trial of CAR T-cell therapy for the treatment of refractory/relapsed ALL in pediatric patients.
As the only National Cancer Institute (NCI)-designated comprehensive cancer center in North Texas, we deliver the best cancer care available today and push to discover new treatments. NCI designation means we offer patients the ability to participate in the broadest possible range of clinical trials, with access to potential therapies not available at other facilities.